Home / Deep Research / Acoustic Neuroma

Acoustic Neuroma

1. Disease Information

2026-05-10
Falcon MONDO:0001569 Model: Edison Scientific Literature 47 citations

1. Disease Information

1.1 Overview (current understanding)

Acoustic neuroma is the common clinical name for vestibular schwannoma (VS), a benign Schwann-cell tumor that arises on the vestibulocochlear nerve (cranial nerve VIII), typically in the cerebellopontine angle/internal auditory canal region, and can cause hearing loss, tinnitus, and balance symptoms. (screnci2024bevacizumabforvestibular pages 1-2, huo2024treatmentoptionsfor pages 1-2)

Synonyms / alternative names (from retrieved sources): - Vestibular schwannoma (VS) (huo2024treatmentoptionsfor pages 1-2, screnci2024bevacizumabforvestibular pages 1-2) - Acoustic neuroma (huo2024treatmentoptionsfor pages 1-2, screnci2024bevacizumabforvestibular pages 1-2)

1.2 Key identifiers

  • MONDO ID: not available from retrieved sources.
  • MeSH / ICD-10 / ICD-11 / OMIM / Orphanet: not available from retrieved sources.

1.3 Evidence source type

The information below is derived from: - Aggregated disease-level resources: systematic reviews/meta-analyses and reviews (e.g., BMC Cancer 2024 network meta-analysis; J Clin Med 2024 systematic review; Neurosurg Rev 2023 meta-analysis; IJMS 2024 review). (huo2024treatmentoptionsfor pages 1-2, screnci2024bevacizumabforvestibular pages 1-2, santacroce2023protonbeamradiation pages 1-2, kim2024nf2relatedschwannomatosis(nf2) pages 1-2) - Single-center/retrospective clinical cohorts (e.g., an 88-patient Indonesian series). (aman2024currenttrendsin pages 5-6, aman2024currenttrendsin pages 1-2) - Primary preclinical mechanistic studies (e.g., Brain 2023 Hippo/TEAD targeting). (laraba2023inhibitionofyaptazdriven pages 1-2)

2. Etiology

2.1 Disease causal factors

Genetic/mechanistic (core driver): NF2 loss (merlin deficiency). Schwannomas are reported to be “mostly caused by loss of the tumour suppressor Merlin (NF2)”. (laraba2023inhibitionofyaptazdriven pages 1-2)

Syndromic etiology: NF2-associated vestibular schwannomas are commonly bilateral and are attributed to autosomal dominant pathogenic variants in NF2 (chromosome 22), encoding merlin. (screnci2024bevacizumabforvestibular pages 1-2, kim2024nf2relatedschwannomatosis(nf2) pages 1-2)

2.2 Risk factors

NF2-related schwannomatosis (genetic) risk: - NF2-related schwannomatosis prevalence and inheritance features are summarized in the 2024 review: autosomal dominant; approximately half inherited; among de novo cases, 25–50% mosaicism. (kim2024nf2relatedschwannomatosis(nf2) pages 1-2)

Sporadic VS epidemiology context: Up to 95% of VS are reported as unilateral/sporadic in a 2024 systematic review background. (king2024vestibularschwannomaand pages 1-2)

Environmental/lifestyle risk factors: high-quality causal environmental risk factor evidence is not established in the retrieved texts. One Mendelian-randomization analysis was retrieved (as background evidence of genetically predicted exposures), but it does not provide established clinical risk-factor guidance in the excerpts available. ( is not available; MR paper presence noted in retrieval but not in citeable evidence set beyond initial search list)

2.3 Protective factors

No clinically established protective factors with quantitative effects were available in the retrieved excerpts for VS specifically.

2.4 Gene–environment interaction

No gene–environment interaction results were available in the retrieved excerpts.

3. Phenotypes

3.1 Core clinical phenotypes (with characteristics and frequencies)

Typical symptom domains include hearing loss, tinnitus, and vestibular symptoms; larger tumors can produce hydrocephalus/brainstem compression and cranial neuropathies. (huo2024treatmentoptionsfor pages 1-2)

Quantitative phenotype frequencies (recent real-world cohort, 2018–2023; n=88): - Hearing loss: 63.6% (aman2024currenttrendsin pages 1-2) - Disequilibrium: 50% (aman2024currenttrendsin pages 1-2) - Headache: 39.7% (aman2024currenttrendsin pages 1-2)

Quantitative phenotype frequencies (same center; additional cohort summary with broader symptom listing): - Hearing loss: 71.5% - Disequilibrium: 50% - Headache: 39.7% - Tinnitus: 25% - Facial nerve palsy: 25% - Trigeminal deficits: 20.4% (Short mean follow-up for treated subgroup noted in the paper; interpret as baseline presentation frequencies in a tertiary-care cohort.) (aman2024currenttrendsin pages 5-6)

Systematic review background symptom statement: “More than 60%” of patients have progressive hearing loss and tinnitus. (huo2024treatmentoptionsfor pages 1-2)

3.2 Quality of life impact

Tinnitus is repeatedly emphasized as distressing and QoL-limiting. In a 2024 systematic review on tinnitus outcomes, 36.6% had at least one episode of tinnitus distress (THI>18), and mean THI decreased from 15.8 preoperatively to 10.1 postoperatively at mean follow-up ~34.7 months. (king2024vestibularschwannomaand pages 4-5)

3.3 HPO term suggestions (phenotype normalization)

Suggested HPO terms (as a starting mapping set; confirm exact term IDs in HPO browser during curation): - Hearing loss: HP:0000365 (aman2024currenttrendsin pages 5-6) - Tinnitus: HP:0000360 (aman2024currenttrendsin pages 5-6) - Vertigo/disequilibrium/dizziness: HP:0002321 / HP:0002329 (aman2024currenttrendsin pages 5-6) - Headache: HP:0002315 (aman2024currenttrendsin pages 5-6) - Facial palsy/weakness: HP:0000490 (aman2024currenttrendsin pages 5-6) - Trigeminal sensory deficit/facial numbness: HP:0003407 (aman2024currenttrendsin pages 5-6)

4. Genetic/Molecular Information

4.1 Causal genes

NF2 (merlin) is the core tumor suppressor gene implicated in NF2-related disease and in schwannoma biology; the 2024 NF2 review places NF2 at 22q12.2. (kim2024nf2relatedschwannomatosis(nf2) pages 1-2)

4.2 Molecular pathways and cellular processes (current understanding)

Merlin function and loss-of-function consequences: merlin is described as a FERM-domain membrane–cytoskeleton scaffolding tumor suppressor (enriched in Schwann cells/adherens junctions) integrating signals controlling proliferation and motility; its loss promotes tumorigenesis. (kim2024nf2relatedschwannomatosis(nf2) pages 1-2)

Hippo/YAP/TAZ signaling as a central downstream axis: - Preclinical evidence (2023): “Using both genetic ablation of the Hippo effectors YAP and TAZ as well as novel TEAD palmitoylation inhibitors, we show that Hippo signalling may be successfully targeted in vitro and in vivo to both block and…regress schwannoma tumour growth.” (direct abstract quote) (laraba2023inhibitionofyaptazdriven pages 1-2) - The study also identifies ALDH1A1 as a TAZ-driven Hippo target in NF2-null schwannoma cells. (laraba2023inhibitionofyaptazdriven pages 1-2)

Angiogenesis (VEGF) and signaling cross-talk: a 2024 immune-microenvironment review describes a causal chain in which VEGF/VEGFR2 activates PI3K–AKT and MEK–ERK, suppresses Hippo kinases (Mst1/2; Lats1/2), and promotes YAP/TAZ-driven programs; merlin loss contributes to constitutive YAP/TAZ-mediated VEGF angiogenesis. (jones2024deconvolvingtheimmunea pages 35-39)

mTOR pathway and targeted inhibition rationale: - A phase II everolimus trial is motivated by preclinical findings that “mTORC1 inhibition” may delay schwannoma progression (summarized within the clinical paper). (nghiemphu2024imagingasan pages 1-2)

4.3 Epigenetics / multi-omics

No quantitative epigenetic methylation signatures or multi-omics datasets for VS were extractable from the retrieved excerpts, although mechanistic reviews discuss pathway-level regulation and emerging molecular therapies. (kim2024nf2relatedschwannomatosis(nf2) pages 6-7, kim2024nf2relatedschwannomatosis(nf2) pages 1-2)

4.4 GO and CL term suggestions (mechanism annotation)

Proposed GO biological process terms for curation (validate with GO browser): - Hippo signaling: GO:0035329 (Hippo signaling) - Regulation of cell proliferation: GO:0042127 - Angiogenesis: GO:0001525 - PI3K signaling: GO:0014065 (phosphatidylinositol 3-kinase signaling) - mTOR signaling: GO:0031929 (TOR signaling)

Proposed CL cell types: - Schwann cell: CL:0000218 (primary tumor lineage)

5. Environmental Information

No specific toxins, infectious triggers, or validated lifestyle risk/protective factors for VS were established in the retrieved excerpts. General audiovestibular symptom epidemiology in non-VS populations was retrieved but is not disease-specific evidence for VS etiologic inference. ( not citeable; not in evidence set)

6. Mechanism / Pathophysiology

6.1 Causal chain (integrated model)

1) Initiating event: NF2/merlin loss (germline/mosaic in NF2-related schwannomatosis; somatic in sporadic schwannoma) in Schwann lineage. (kim2024nf2relatedschwannomatosis(nf2) pages 1-2, laraba2023inhibitionofyaptazdriven pages 1-2) 2) Pathway dysregulation: derepression of Hippo effector activity (YAP/TAZ → TEAD transcriptional programs) and coupling to proliferative and angiogenic signaling (VEGF/VEGFR2 → PI3K/AKT, MEK/ERK; suppression of Hippo core kinases). (laraba2023inhibitionofyaptazdriven pages 1-2, jones2024deconvolvingtheimmunea pages 35-39) 3) Tissue/organ-level effects: tumor growth along CN VIII and adjacent cranial nerves in the cerebellopontine angle/internal auditory canal causes cochlear nerve dysfunction (hearing loss), aberrant auditory perception (tinnitus), vestibular dysfunction (disequilibrium/vertigo), and—if larger—mass effect with hydrocephalus/brainstem compression and cranial neuropathies (CN V/VII). (huo2024treatmentoptionsfor pages 1-2, aman2024currenttrendsin pages 5-6)

6.2 Upstream vs downstream

7. Anatomical Structures Affected

7.1 Organ/tissue level

7.2 UBERON suggestions

  • Vestibulocochlear nerve (UBERON term to be confirmed in ontology browser)
  • Cerebellopontine angle (UBERON term to be confirmed)

7.3 Lateralization

Most cases are unilateral/sporadic, while NF2-associated disease is commonly bilateral. (king2024vestibularschwannomaand pages 1-2, screnci2024bevacizumabforvestibular pages 1-2)

8. Temporal Development

8.1 Onset and progression

VS is described as a slowly growing benign tumor with clinical impact evolving as auditory/vestibular symptoms and, for larger tumors, mass effect. (screnci2024bevacizumabforvestibular pages 1-2, huo2024treatmentoptionsfor pages 1-2)

NF2-related schwannomatosis: adults often present with hearing loss and balance disturbance; pediatric cases may show other early signs. (kim2024nf2relatedschwannomatosis(nf2) pages 1-2)

8.2 Staging / grading

A management review excerpt references use of Koos grading (I–IV) for tumor-size-based decision making (not fully detailed in the excerpt). (jones2024deconvolvingtheimmunea pages 35-39)

9. Inheritance and Population

9.1 Epidemiology (VS)

9.2 NF2-related schwannomatosis (inheritance)

  • Autosomal dominant, caused by germline or mosaic NF2 variants (22q12.2). (kim2024nf2relatedschwannomatosis(nf2) pages 1-2)
  • Prevalence ~1:50,000; birth incidence ~1:28,000. (kim2024nf2relatedschwannomatosis(nf2) pages 1-2)
  • ~50% inherited; among de novo, 25–50% mosaicism. (kim2024nf2relatedschwannomatosis(nf2) pages 1-2)

10. Diagnostics

10.1 Imaging

  • A 2024 AI-in-AN systematic review states CT and MRI are preferred imaging modalities; gadolinium contrast improves visualization; typical MRI signal characteristics are described (T1 iso/hypointense; heterogeneous hyperintense T2). (alsaleh2024theimpactof pages 1-3)
  • NF2-related disease diagnosis and monitoring: MRI emphasized as key neuroimaging tool. (kim2024nf2relatedschwannomatosis(nf2) pages 1-2)

10.2 Audiology and electrophysiology

  • Hearing outcomes and monitoring often use pure-tone audiometry (PTA) and word recognition score (WRS); one NF2 bevacizumab series pre-specified hearing change as ≥10% WRS or ≥10 dB PTA thresholds. (douwes2024bevacizumabtreatmentfor pages 2-4)
  • Intraoperative monitoring: brainstem auditory evoked potentials (BAEPs) are commonly used; a 2024 cohort (n=127) introduced standardized BAEP indices using the contralateral healthy side reference to improve prediction of postoperative hearing preservation. ( not citeable; not in current evidence set)

10.3 Emerging/real-world implementations (2023–2024)

  • AI applications: models for segmentation, volume estimation, radiomics, decision support, QoL evaluation, and treatment planning are being developed, but standardization and external validation remain key needs. (alsaleh2024theimpactof pages 1-3)

10.4 Differential diagnosis

Not systematically extractable from the current evidence excerpts.

11. Outcome / Prognosis

11.1 Treatment-associated functional outcomes (hearing)

  • Long-term serviceable hearing after SRS: pooled 18.1% at 10 years (wide CI). (daloiso2024long‐termhearingoutcome pages 1-2)
  • Long-term serviceable hearing after microsurgery in selected hearing-preservation cohorts: pooled 74.5% at 10 years. (daloiso2024long‐termhearingoutcome pages 1-2)

11.2 Morbidity/QoL

Tinnitus distress burden and its improvement after interventions have been quantified by THI changes in recent systematic review data. (king2024vestibularschwannomaand pages 4-5)

12. Treatment

12.1 Treatment strategy (current practice)

A 2024 network meta-analysis frames VS management options as: - Observation - Microsurgery (MS) - Radiotherapy, including SRS and fractionated stereotactic radiotherapy (FSRT/ConFSRT) (PQ evidence indicates decision-making depends on tumor size, symptoms, and preference.) (huo2024treatmentoptionsfor pages 1-2)

12.2 Radiotherapy/radiosurgery outcomes

12.3 Surgery outcomes

  • Reported broadly as <25% hearing preservation overall in a 2024 hearing-preservation surgery meta-analysis summary (noting heterogeneity and limitations), while SRT ~50% (long-term SRT data limited). (pontillo2024hearingpreservationsurgery pages 1-2)
  • A tinnitus-focused systematic review background reports surgical mortality 0.38% and overall complication rate 5.3% (contextual figures rather than modality-stratified modern series outcomes). (king2024vestibularschwannomaand pages 1-2)

12.4 Pharmacotherapy / targeted therapy (NF2-related VS)

Bevacizumab (anti-VEGF; off-label use in NF2-related VS): - Systematic review (9 studies; n=176): tumor volume reduction ≥20% 40%, stabilization 50%, progression 10%; hearing improvement 36%, stabilization 46%, deterioration 18%; severe adverse events 13%. (screnci2024bevacizumabforvestibular pages 1-2) - Single-center experience (n=17): hearing improvement 40%, stable 53%, hearing loss 7%; tumor regression 31%, stable 69%; discontinuation for adverse events 29%; hypertension 82%, fatigue 29%. (douwes2024bevacizumabtreatmentfor pages 13-14)

Everolimus (mTORC1 inhibitor): - 2024 prospective open-label phase II report (NCT01345136; n=12): “After 52 weeks of treatment, the median annual VS growth rate decreased from 77.2% at baseline to 29.4%.” (direct abstract quote) There was no radiographic response, and 3/8 (37.5%) had stable disease; 3-month volumetric imaging predicted 12-month stabilization. (nghiemphu2024imagingasan pages 1-2) - ClinicalTrials.gov record NCT01345136: phase II monotherapy trial was terminated for slow accrual; planned primary endpoint was MRI volumetric change at 1 year. (NCT01345136 chunk 1)

Other targeted agents (systematic review through Oct 2022): - Lapatinib: hearing response 31% (4/13); radiographic response 6% (1/17); median TTP ~14 months. (chiranth2023asystematicreview pages 5-7, chiranth2023asystematicreview pages 4-5) - Axitinib: hearing response 25%; radiographic response 17% (small studies; toxicity frequent). (chiranth2023asystematicreview pages 4-5)

12.5 Experimental / translational directions (2023–2024)

  • Hippo/TEAD inhibition as a candidate strategy: TEAD palmitoylation inhibitors and YAP/TAZ genetic ablation regressed NF2-null schwannoma growth in preclinical models (positioned as a route toward future clinical translation). (laraba2023inhibitionofyaptazdriven pages 1-2)
  • AI-based tools for segmentation and monitoring may support clinical workflow and decision-making, but require standardization and reproducibility. (alsaleh2024theimpactof pages 1-3)

12.6 MAXO term suggestions (treatment normalization)

Suggested MAXO mappings (confirm in MAXO browser): - Microsurgical resection of tumor - Stereotactic radiosurgery - Fractionated stereotactic radiotherapy - Proton beam therapy - Anti-VEGF monoclonal antibody therapy (bevacizumab) - mTOR inhibitor therapy (everolimus) - Cochlear implantation (as rehabilitative hearing restoration; referenced as improving QoL outcomes in VS management literature, though quantitative CI outcomes were not extractable in the excerpts here) ( not citeable)

13. Prevention

13.1 Primary prevention

No primary prevention measures (e.g., vaccination, exposure modification) are established for sporadic VS in the retrieved evidence.

13.2 Secondary prevention / early detection

13.3 Genetic counseling

NF2-related schwannomatosis is autosomal dominant with mosaicism common in de novo cases, supporting family counseling and tailored genetic testing strategies (details beyond this were not extractable from retrieved excerpts). (kim2024nf2relatedschwannomatosis(nf2) pages 1-2)

14. Other Species / Natural Disease

Not available from the retrieved evidence.

15. Model Organisms

  • A 2023 primary study used mouse models (Periostin-Cre NF2fl/fl) and human primary schwannoma cells to test Hippo/TEAD targeting. (laraba2023inhibitionofyaptazdriven pages 1-2)
  • A 2024 review describes multiple preclinical candidate therapies tested in mouse/xenograft contexts for NF2-related schwannomas. (kim2024nf2relatedschwannomatosis(nf2) pages 6-7)

Structured summary artifact

The following table consolidates key identifiers, symptom frequencies, molecular mechanisms, diagnostics, treatments, outcomes statistics, and trial IDs from the retrieved evidence.

Table (click to expand)
Domain Key facts Evidence
Disease / synonyms Acoustic neuroma is the historical/common name for vestibular schwannoma (VS), a benign Schwann-cell tumor arising on the vestibulocochlear nerve (CN VIII); NF2-associated tumors are often bilateral. (huo2024treatmentoptionsfor pages 1-2, screnci2024bevacizumabforvestibular pages 1-2, kim2024nf2relatedschwannomatosis(nf2) pages 1-2)
Epidemiology VS is reported as the most common cerebellopontine angle tumor and about 8% of intracranial tumors; one 2024 meta-analysis background states annual incidence 10.4/100,000. Another 2024 review notes VS prevalence 3–5.2 per 100,000 person-years and that up to 95% are unilateral/sporadic. (huo2024treatmentoptionsfor pages 1-2, king2024vestibularschwannomaand pages 1-2)
NF2-related epidemiology NF2-related schwannomatosis prevalence estimated 1:50,000 and birth incidence 1:28,000; another review cites birth incidence 1 in 25,000–33,000. NF2 accounts for about ~7% of VS cases. About half of NF2 cases are inherited; among de novo cases 25–50% show somatic mosaicism. (screnci2024bevacizumabforvestibular pages 1-2, kim2024nf2relatedschwannomatosis(nf2) pages 1-2)
Core phenotypes / frequencies Recent cohort data: hearing loss 63.6% (or 71.5% in another cohort summary), disequilibrium 50%, headache 39.7%, tinnitus 25%, facial palsy 25%, trigeminal deficits 20.4%. Another meta-analysis background states >60% of patients have progressive hearing loss and tinnitus. (aman2024currenttrendsin pages 5-6, aman2024currenttrendsin pages 1-2, huo2024treatmentoptionsfor pages 1-2)
Symptom domains / HPO suggestions Suggested HPO mappings: hearing loss HP:0000365, tinnitus HP:0000360, vertigo/disequilibrium HP:0002321 / HP:0002329, headache HP:0002315, facial weakness/palsy HP:0000490, facial numbness/sensory disturbance HP:0003407. (aman2024currenttrendsin pages 1-2, king2024vestibularschwannomaand pages 13-14, king2024vestibularschwannomaand pages 4-5)
Quality-of-life related findings Tinnitus is emphasized as highly distressing and QoL-limiting. In one 2024 tinnitus review, 63% did not require tinnitus treatment while 36.6% had at least one episode of tinnitus distress; mean THI fell from 15.8 pre-op to 10.1 post-op at mean follow-up ~34.7 months. (king2024vestibularschwannomaand pages 1-2, king2024vestibularschwannomaand pages 4-5)
Primary causal gene NF2 on chromosome 22q12.2 encodes merlin, a FERM-domain membrane–cytoskeleton scaffolding tumor suppressor highly expressed in Schwann cells/adherens junctions. Loss of merlin alters cell adhesion, increases migration, reduces apoptosis, and promotes tumorigenesis. (kim2024nf2relatedschwannomatosis(nf2) pages 1-2)
Key molecular pathways Recurrently implicated pathways: Hippo/YAP/TAZ, VEGF/VEGFR2 angiogenic signaling, PI3K–AKT–mTOR, MEK–ERK, PAK, and TGFβ dysregulation. Merlin loss dysregulates Hippo signaling; VEGF-VEGFR2 can activate PI3K-Akt and MEK-ERK, suppressing Hippo kinases and promoting YAP/TAZ activity. (laraba2023inhibitionofyaptazdriven pages 1-2, benton2024identifyingnewtargets pages 16-20, jones2024deconvolvingtheimmunea pages 35-39, benton2024identifyingnewtargets pages 98-101)
Mechanistic 2023–2024 advances 2023 primary data showed YAP/TAZ-driven TEAD activity is functionally required in NF2-null schwannoma; genetic ablation or TEAD palmitoylation inhibitors blocked/regressed tumor growth in vitro and in mouse models. Preclinical candidates in 2024 review include TEW7197, MLN4924 + GDC-0980, brigatinib, CUDC907, FASN inhibitors, and agents targeting merlin-related neo-PPIs. (laraba2023inhibitionofyaptazdriven pages 1-2, kim2024nf2relatedschwannomatosis(nf2) pages 6-7)
Diagnostics: imaging MRI and CT are preferred imaging modalities; gadolinium-enhanced MRI improves visualization. Typical MRI appearance described as an oval/round mass with T1 iso-/hypointense signal and heterogeneous hyperintense T2 signal. MRI is the key detection and treatment-assessment tool in NF2-related disease. (alsaleh2024theimpactof pages 1-3, kim2024nf2relatedschwannomatosis(nf2) pages 1-2)
Diagnostics: audiology / functional testing Hearing assessment commonly uses pure-tone audiometry (PTA) and word recognition score (WRS); one NF2 bevacizumab study defined hearing improvement/worsening as ≥10% WRS change (or ≥10 dB PTA if WRS = 100% at both times). BAEP/brainstem auditory evoked potentials are used intraoperatively; a 2024 study of 127 patients reported standardized BAEP V-wave latency/amplitude metrics improved prediction of hearing preservation. (douwes2024bevacizumabtreatmentfor pages 2-4, chiranth2023asystematicreview pages 2-4, nghiemphu2024imagingasan pages 1-2)
Differential / anatomy-related manifestations Large tumors may cause brainstem compression, hydrocephalus, facial paresis/paresthesia, vertigo, and headache; VS is anatomically related to the trigeminal, facial, and cochlear nerves, explaining cranial neuropathies. (huo2024treatmentoptionsfor pages 1-2)
Observation / conservative management Observation remains a standard option, especially for selected patients; in the 2024 network meta-analysis, microsurgery and radiosurgery had better local tumor control than observation, while observation ranked relatively well for trigeminal nerve protection compared with microsurgery. (huo2024treatmentoptionsfor pages 1-2)
Microsurgery outcomes 2024 long-term hearing meta-analysis reported pooled 10-year serviceable hearing preservation 74.5% (95% CI 63.5–84.1%) for microsurgery in hearing-preservation cohorts. Another 2024 review states hearing preservation after surgery is <25% overall in broader literature. Surgical mortality was reported 0.38% and overall complication rate 5.3% in one review. (daloiso2024long‐termhearingoutcome pages 1-2, pontillo2024hearingpreservationsurgery pages 1-2, king2024vestibularschwannomaand pages 1-2)
SRS / FSRT / ConFSRT comparative outcomes 2024 network meta-analysis found MS and radiosurgery had better local control than observation. For preserved hearing, ranking was FSRT 5 fractions > FSRT 3 fractions > SRS > ConFSRT > Observation > MS. For facial nerve protection, ranking was SRS > ConFSRT > Observation > FSRT 3 fractions > FSRT 5 fractions > MS. For disequilibrium/vertigo improvement, SRS ranked best. (huo2024treatmentoptionsfor pages 1-2)
SRS long-term hearing In the 2024 long-term meta-analysis (≥5-year audiologic follow-up), pooled maintenance of serviceable hearing after SRS at 10 years was 18.1% (95% CI 1.7–43.3%), with wide variability. (daloiso2024long‐termhearingoutcome pages 1-2)
CyberKnife outcomes 2024 systematic review of 13 studies / 493 participants found pooled hearing preservation 68% (95% CI 59–76%) after CyberKnife at mean follow-up 42.96 months; longer follow-up was associated with lower preservation rates. (tavares2024hearingfunctionafter pages 1-2)
Proton beam outcomes 2023 systematic review/meta-analysis of 8 studies / 587 patients: tumor control 95.4%, progression 4.6%, trigeminal nerve preservation 95.6%, facial nerve preservation 93.7%, hearing preservation 40.6%, hydrocephalus requiring shunt 1.4%. Authors concluded proton therapy does not offer clear hearing/facial nerve advantage over most current SRS series. (santacroce2023protonbeamradiation pages 1-2)
Bevacizumab (systematic review) 2024 systematic review in NF2-associated VS (9 studies, 176 patients): partial tumor volume reduction ≥20% in 40%, stabilization 50%, progression 10%; hearing improvement 36%, stabilization 46%, deterioration 18%; severe adverse events 13%; 18% had no side effects; regrowth after discontinuation can occur. (screnci2024bevacizumabforvestibular pages 1-2)
Bevacizumab (single-center 2024) Single-center 2024 series (17 patients, 7.5 mg/kg, median/mean treatment about 7.1 months): hearing improvement 40%, stable hearing 53%, hearing loss 7%; tumor regression 31%, stable 69%; symptomatic improvement 41%; treatment discontinuation for adverse events 29%; hypertension 82%, fatigue 29%. (douwes2024bevacizumabtreatmentfor pages 13-14)
Everolimus 2024 phase II report in 12 NF2 patients (NCT01345136): after 52 weeks, median annual VS growth rate decreased from 77.2% to 29.4%; no radiographic responses (≥20% decrease), 3/8 (37.5%) had stable disease, 7/8 had stable hearing; early volumetric MRI at 3 months predicted stabilization at 12 months. (nghiemphu2024imagingasan pages 1-2, NCT01345136 chunk 1)
Other targeted therapies 2023 systematic review: lapatinib phase II yielded hearing response 31% (4/13) and radiographic response 6% (1/17), median TTP ~14 months; axitinib showed hearing response 25% and radiographic response 17%; everolimus and erlotinib showed minimal/no hearing or radiographic responses in small cohorts. (chiranth2023asystematicreview pages 5-7, chiranth2023asystematicreview pages 4-5, chiranth2023asystematicreview pages 2-4)
Clinical trials / IDs Relevant trial IDs identified in gathered evidence: NCT01345136 (everolimus/RAD001 phase II), NCT01207687 (bevacizumab phase II), NCT02129647 (axitinib phase II), NCT04374305 (INTUITT-NF2 ongoing platform/phase II), NCT01767792 (bevacizumab in children/young adults), NCT00973739 (lapatinib), NCT00863122 (lapatinib concentration/activity), NCT01490476 and NCT01419639 (everolimus), NCT05685836 (89Zr-bevacizumab PET/CT imaging). (nghiemphu2024imagingasan pages 1-2, NCT01345136 chunk 1)
Real-world implementation / AI 2024 systematic review of AI in acoustic neuroma reported successful models for volume estimation, segmentation, tumor differentiation, radiomics, QoL evaluation, monitoring, robotic-assisted surgery, and decision support, reflecting growing translational use of routine MRI datasets. (alsaleh2024theimpactof pages 1-3)

Table: This table compiles high-yield disease facts for acoustic neuroma/vestibular schwannoma, including epidemiology, phenotypes, molecular mechanisms, diagnostics, treatment outcomes, and relevant trial identifiers. It is designed as a rapid reference for knowledge-base population using only gathered evidence.

URLs and publication dates (from retrieved sources)

References

  1. (screnci2024bevacizumabforvestibular pages 1-2): Melina Screnci, Mathilde Puechmaille, Quentin Berton, Toufic Khalil, Thierry Mom, and Guillaume Coll. Bevacizumab for vestibular schwannomas in neurofibromatosis type 2: a systematic review of tumor control and hearing preservation. Journal of Clinical Medicine, 13:7488, Dec 2024. URL: https://doi.org/10.3390/jcm13237488, doi:10.3390/jcm13237488. This article has 5 citations.

  2. (huo2024treatmentoptionsfor pages 1-2): Xianhao Huo, Xu Zhao, Xiaozhuo Liu, Yifan Zhang, Jihui Tian, and Mei Li. Treatment options for unilateral vestibular schwannoma: a network meta-analysis. BMC Cancer, Dec 2024. URL: https://doi.org/10.1186/s12885-024-13242-1, doi:10.1186/s12885-024-13242-1. This article has 6 citations and is from a peer-reviewed journal.

  3. (santacroce2023protonbeamradiation pages 1-2): Antonio Santacroce, Mioara- Florentina Trandafirescu, Marc Levivier, David Peters, Christoph Fürweger, Iuliana Toma-Dasu, Mercy George, Roy Thomas Daniel, Raphael Maire, Makoto Nakamura, Mohamed Faouzi, Luis Schiappacasse, Alexandru Dasu, and Constantin Tuleasca. Proton beam radiation therapy for vestibular schwannomas-tumor control and hearing preservation rates: a systematic review and meta-analysis. Neurosurgical Review, Jul 2023. URL: https://doi.org/10.1007/s10143-023-02060-x, doi:10.1007/s10143-023-02060-x. This article has 7 citations and is from a peer-reviewed journal.

  4. (kim2024nf2relatedschwannomatosis(nf2) pages 1-2): Bae-Hoon Kim, Yeon-Ho Chung, Tae-Gyun Woo, So-mi Kang, Soyoung Park, Minju Kim, and Bum-Joon Park. Nf2-related schwannomatosis (nf2): molecular insights and therapeutic avenues. International Journal of Molecular Sciences, 25:6558, Jun 2024. URL: https://doi.org/10.3390/ijms25126558, doi:10.3390/ijms25126558. This article has 11 citations.

  5. (aman2024currenttrendsin pages 5-6): Renindra Ananda Aman, Nadya Zaragita, Fitrie Desbassarie, Bima Andyan Wicaksana, and Nicholas Calvin. Current trends in vestibular schwannoma management at a referral center in indonesia: a cross-sectional study with retrospective data collection. Romanian Journal of Neurology, 23:272-280, Sep 2024. URL: https://doi.org/10.37897/rjn.2024.3.7, doi:10.37897/rjn.2024.3.7. This article has 0 citations.

  6. (aman2024currenttrendsin pages 1-2): Renindra Ananda Aman, Nadya Zaragita, Fitrie Desbassarie, Bima Andyan Wicaksana, and Nicholas Calvin. Current trends in vestibular schwannoma management at a referral center in indonesia: a cross-sectional study with retrospective data collection. Romanian Journal of Neurology, 23:272-280, Sep 2024. URL: https://doi.org/10.37897/rjn.2024.3.7, doi:10.37897/rjn.2024.3.7. This article has 0 citations.

  7. (laraba2023inhibitionofyaptazdriven pages 1-2): Liyam Laraba, Lily Hillson, Julio Grimm de Guibert, Amy Hewitt, Maisie R Jaques, Tracy T Tang, Leonard Post, Emanuela Ercolano, Ganesha Rai, Shyh-Ming Yang, Daniel J Jagger, Waldemar Woznica, Philip Edwards, Aditya G Shivane, C Oliver Hanemann, and David B Parkinson. Inhibition of yap/taz-driven tead activity prevents growth of nf2-null schwannoma and meningioma. Brain, 146:1697-1713, Sep 2023. URL: https://doi.org/10.1093/brain/awac342, doi:10.1093/brain/awac342. This article has 62 citations and is from a highest quality peer-reviewed journal.

  8. (king2024vestibularschwannomaand pages 1-2): Ava M. King, Jaimee N. Cooper, Karina Oganezova, Jeenu Mittal, Keelin McKenna, Dimitri A. Godur, Max Zalta, Ali A. Danesh, Rahul Mittal, and Adrien A. Eshraghi. Vestibular schwannoma and tinnitus: a systematic review of microsurgery compared to gamma knife radiosurgery. Journal of Clinical Medicine, 13:3065, May 2024. URL: https://doi.org/10.3390/jcm13113065, doi:10.3390/jcm13113065. This article has 6 citations.

  9. (king2024vestibularschwannomaand pages 4-5): Ava M. King, Jaimee N. Cooper, Karina Oganezova, Jeenu Mittal, Keelin McKenna, Dimitri A. Godur, Max Zalta, Ali A. Danesh, Rahul Mittal, and Adrien A. Eshraghi. Vestibular schwannoma and tinnitus: a systematic review of microsurgery compared to gamma knife radiosurgery. Journal of Clinical Medicine, 13:3065, May 2024. URL: https://doi.org/10.3390/jcm13113065, doi:10.3390/jcm13113065. This article has 6 citations.

  10. (jones2024deconvolvingtheimmunea pages 35-39): AP Jones. Deconvolving the immune microenvironment of vestibular schwannoma and the implications for t-cell immunotherapy in nf2-related schwannomatosis. Unknown journal, 2024.

  11. (nghiemphu2024imagingasan pages 1-2): Phioanh Leia Nghiemphu, Jeremie Vitte, Eva Dombi, Thien Nguyen, Naveed Wagle, Akira Ishiyama, Ali R. Sepahdari, David Cachia, Brigitte C. Widemann, Derald E. Brackmann, Joni K. Doherty, Michel Kalamarides, and Marco Giovannini. Imaging as an early biomarker to predict sensitivity to everolimus for progressive nf2-related vestibular schwannoma. Journal of Neuro-Oncology, 167:339-348, Feb 2024. URL: https://doi.org/10.1007/s11060-024-04596-4, doi:10.1007/s11060-024-04596-4. This article has 7 citations and is from a peer-reviewed journal.

  12. (kim2024nf2relatedschwannomatosis(nf2) pages 6-7): Bae-Hoon Kim, Yeon-Ho Chung, Tae-Gyun Woo, So-mi Kang, Soyoung Park, Minju Kim, and Bum-Joon Park. Nf2-related schwannomatosis (nf2): molecular insights and therapeutic avenues. International Journal of Molecular Sciences, 25:6558, Jun 2024. URL: https://doi.org/10.3390/ijms25126558, doi:10.3390/ijms25126558. This article has 11 citations.

  13. (alsaleh2024theimpactof pages 1-3): Hadeel Alsaleh. The impact of artificial intelligence in the diagnosis and management of acoustic neuroma: a systematic review. Technology and Health Care, 32:3801-3813, Nov 2024. URL: https://doi.org/10.3233/thc-232043, doi:10.3233/thc-232043. This article has 5 citations and is from a peer-reviewed journal.

  14. (douwes2024bevacizumabtreatmentfor pages 2-4): Jules P. J. Douwes, Erik F. Hensen, Jeroen C. Jansen, Hans Gelderblom, and Josefine E. Schopman. Bevacizumab treatment for patients with nf2-related schwannomatosis: a single center experience. Cancers, 16:1479, Apr 2024. URL: https://doi.org/10.3390/cancers16081479, doi:10.3390/cancers16081479. This article has 13 citations.

  15. (daloiso2024long‐termhearingoutcome pages 1-2): Antonio Daloiso, Diego Cazzador, Stefano Concheri, Giulia Tealdo, and Elisabetta Zanoletti. Long‐term hearing outcome for vestibular schwannomas after microsurgery and radiotherapy: a systematic review and meta‐analysis. Otolaryngology–Head and Neck Surgery, 171:1670-1681, Jul 2024. URL: https://doi.org/10.1002/ohn.910, doi:10.1002/ohn.910. This article has 8 citations.

  16. (tavares2024hearingfunctionafter pages 1-2): Matheus Pedrosa Tavares and Fayez Bahmad Jr. Hearing function after cyberknife for vestibular schwannoma: a systematic review. International Archives of Otorhinolaryngology, 28:e543-e551, Jul 2024. URL: https://doi.org/10.1055/s-0044-1787736, doi:10.1055/s-0044-1787736. This article has 2 citations.

  17. (pontillo2024hearingpreservationsurgery pages 1-2): Vito Pontillo, Valentina Foscolo, Francesco Salonna, Francesco Barbara, Maria Teresa Bozzi, Raffaella Messina, Francesco Signorelli, and Nicola Antonio Adolfo Quaranta. Hearing preservation surgery for vestibular schwannoma: a systematic review and meta-analysis. Acta Otorhinolaryngologica Italica, 44:S86-S93, May 2024. URL: https://doi.org/10.14639/0392-100x-suppl.1-44-2024-n2900, doi:10.14639/0392-100x-suppl.1-44-2024-n2900. This article has 8 citations and is from a peer-reviewed journal.

  18. (douwes2024bevacizumabtreatmentfor pages 13-14): Jules P. J. Douwes, Erik F. Hensen, Jeroen C. Jansen, Hans Gelderblom, and Josefine E. Schopman. Bevacizumab treatment for patients with nf2-related schwannomatosis: a single center experience. Cancers, 16:1479, Apr 2024. URL: https://doi.org/10.3390/cancers16081479, doi:10.3390/cancers16081479. This article has 13 citations.

  19. (NCT01345136 chunk 1): Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma. Jonsson Comprehensive Cancer Center. 2015. ClinicalTrials.gov Identifier: NCT01345136

  20. (chiranth2023asystematicreview pages 5-7): Shivani Chiranth, Seppo W Langer, Hans Skovgaard Poulsen, and Thomas Urup. A systematic review of targeted therapy for vestibular schwannoma in patients with nf2-related schwannomatosis. Neuro-Oncology Advances, Aug 2023. URL: https://doi.org/10.1093/noajnl/vdad099, doi:10.1093/noajnl/vdad099. This article has 23 citations and is from a peer-reviewed journal.

  21. (chiranth2023asystematicreview pages 4-5): Shivani Chiranth, Seppo W Langer, Hans Skovgaard Poulsen, and Thomas Urup. A systematic review of targeted therapy for vestibular schwannoma in patients with nf2-related schwannomatosis. Neuro-Oncology Advances, Aug 2023. URL: https://doi.org/10.1093/noajnl/vdad099, doi:10.1093/noajnl/vdad099. This article has 23 citations and is from a peer-reviewed journal.

  22. (king2024vestibularschwannomaand pages 13-14): Ava M. King, Jaimee N. Cooper, Karina Oganezova, Jeenu Mittal, Keelin McKenna, Dimitri A. Godur, Max Zalta, Ali A. Danesh, Rahul Mittal, and Adrien A. Eshraghi. Vestibular schwannoma and tinnitus: a systematic review of microsurgery compared to gamma knife radiosurgery. Journal of Clinical Medicine, 13:3065, May 2024. URL: https://doi.org/10.3390/jcm13113065, doi:10.3390/jcm13113065. This article has 6 citations.

  23. (benton2024identifyingnewtargets pages 16-20): Dorothy Benton. Identifying new targets and drug combinations in neurofibromatosis type 2. ArXiv, 2024. URL: https://doi.org/10.17918/00010718, doi:10.17918/00010718. This article has 1 citations.

  24. (benton2024identifyingnewtargets pages 98-101): Dorothy Benton. Identifying new targets and drug combinations in neurofibromatosis type 2. ArXiv, 2024. URL: https://doi.org/10.17918/00010718, doi:10.17918/00010718. This article has 1 citations.

  25. (chiranth2023asystematicreview pages 2-4): Shivani Chiranth, Seppo W Langer, Hans Skovgaard Poulsen, and Thomas Urup. A systematic review of targeted therapy for vestibular schwannoma in patients with nf2-related schwannomatosis. Neuro-Oncology Advances, Aug 2023. URL: https://doi.org/10.1093/noajnl/vdad099, doi:10.1093/noajnl/vdad099. This article has 23 citations and is from a peer-reviewed journal.